ArticleIranian biomedical journal2025
Antioxidant Potentials, Protease Inhibitory, and Cytotoxic Activities of Various Isolated Extracts from Salvia aegyptiaca.
Article in Iranian biomedical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Natural compounds can regulate the growth and progression of cancer cells with low toxicity to normal cell; therefore, these compounds are unique targets for cancer treatment. Recently, extracts from Salvia species have shown promising antiproliferative potential. This study aimed to isolate and characterize bioactive compounds from Salvia aegyptiaca and evaluate their antioxidant, cytotoxic, and protease-inhibitory activities. Methods: In this study, various extracts of S. aegyptiaca were prepared, and several compounds, including ursolic acid, oleanolic acid, luteolin-7-O-glucoside, quercetin-3-O-rutoside, and rosmarinic acid, were isolated and characterized using different spectroscopic methods. Finally, the antioxidant activity, protease inhibitory activity, and cytotoxicity of the crude extract, multiple fractions, and isolated compounds were examined. Results: According to the results obtained, rosmarinic acid demonstrated the highest antioxidant performance, as indicated by the following assays: DPPH (IC50: 28.39 ± 0.75 µg/mL), ABTS (39.52 ± 0.72 µg/mL), FRAP (31.87 ± 0.67 µg/mL), NO scavenging (71.44 ± 1.04 µg/mL), and ORAC values (0.6 TE/mg). Furthermore, both cynaroside and rosmarinic acid exhibited the most potent antiproliferative effects against the Hep G2 cell line, with IC50 value of 34.4 ± 2.34 and 47.84 ± 5.87 µg/mL, respectively. The EtOAc fraction and rosmarinic acid also showed higher protease inhibitory activity, with IC50 of 17.6 ± 0.10 and 17.0 ± 0.30 µg/mL, respectively, as compared to other compounds. Conclusion: Our findings suggest that the identified compounds may be responsible for the antiproliferative effects of S. aegyptiaca. Overall, S. aegyptiaca could serve as a valuable natural antioxidant and anticancer agent in both pharmaceutical and food industries
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.